Hythiam Contact: Investment Community: Media Relations
Sanjay Sabnani Paul Henning Angelyn Lechman
(310) 444-5335 Cameron Associates Chase Communications
email@example.com (212) 554-5462 (619) 223-0961
LEADING NEW YORK ADDICTION TREATMENT CENTER TO LICENSE PROMETA™
PROTOCOL FOR TREATING THOSE ADDICTED
TO COCAINE AND METHAMPHETAMINE
NYC cocaine use is twice national average and methamphetamine use among
Gay community escalating rapidly
LOS ANGELES, Calif. —September 26, 2005— Hythiam, Inc. (NASDAQ: HYTM), a healthcare
services management company that delivers to treatment providers proprietary administrative
services and physiological protocols designed to treat substance dependence, announced today that it
has signed a licensing and services agreement to offer its PROMETA™ treatment protocols for cocaine
and methamphetamine dependence to the Parallax Center in New York City, a leading substance
abuse treatment facility.
The Parallax Center has been operating in New York City since 1984 and known as one of the top
substance dependency treatment providers in the New York area. The Center also provides intensive
outpatient services for behavioral health and is a preferred provider of reimbursed substance abuse
treatment to the largest membership based HMO in the City- HIP Health Plan of New York.
“Parallax prides itself on offering the most innovative medical treatments to patients, like the
PROMETA™ protocols. The City is renowned for leading the nation in almost every area, and its
residents now have a new treatment option that can be the first critical step towards recovery from
stimulant dependence,” said Dr. David Ockert, Ph.D., Executive Director of the Parallax Center.
Dr. Ockert is the founder of the Parallax Center and is a trained clinician, researcher and statistician
with extensive experience developing and evaluating integrated behavioral and pharmacological
treatments. Dr. Ockert has developed and elaborated on methodologies for out-patient detoxification
and stabilization from alcohol, opiates, benzodiazepines, stimulants, and other drugs of abuse.
Dr. Ockert was awarded a National Institute of Mental Health (NIMH) Research Training Fellowship for
Columbia University. Dr. Ockert had graduate-level teaching appointments at New York University
and Columbia University and has lectured at the Center for Alcohol Studies, Rutgers University. He
has provided consulting, clinical research, medical and technical advisory services for many
organizations and has published six journal articles and four chapters specifically regarding lowered
drug use recidivism following psychotropic medication (alcohol, opiates, and stimulants) and most
recently, co-authored a chapter on the treatment of stimulant dependence for Guilford Press (2004).
“While alcoholism is prevalent nationwide, New York has been hard hit by stimulant abuse with
cocaine use among adults at twice the national average, and methamphetamine use rapidly
escalating- especially among the City’s gay community,” said Hythiam’s Chairman and CEO Terren
Peizer. “Methamphetamine, which compromises the immune system, removes inhibitions, heightens
libido and sexual intensity, and has been cited as a primary cause for increases in HIV and other
sexually transmitted diseases. In New York City, HIV diagnosis increased every year from 2000-
2003 in the gay community, while remaining stable for the rest of the population.
“We are proud to partner with Dr. Ockert and Parallax in offering the PROMETA™ protocols as a way to
seek to combat stimulant dependency and make a powerful, positive impact on the lives of families
and communities in New York.
“The value of having an acute medical intervention in lieu of a lengthy residential treatment center
stay has tremendous appeal to the busy professionals of New York City, especially to those who work
in the financial community,” Peizer continued, “As a public company, we have been fortunate that
many of our shareholders, sponsors, or their loved ones have heard about and benefited from the
PROMETA™ treatment protocols through their due diligence on us. Now through Parallax, they will
have a world class treatment center that can offer them convenient PROMETA™ treatment on an
About the Parallax Center
The Parallax Center is a medically supervised substance abuse treatment program in New York City,
operating since 1984. The Office of Alcoholism and Substance Abuse Services of the State of New
York licenses two treatment services within the Parallax Center: medically-supervised ambulatory
withdrawal services and outpatient chemical dependence treatment services. The Parallax Center
treats dependence on alcohol, opiates, stimulants, sedatives/tranquilizers, and all other common
substances of abuse.
Hythiam's PROMETA™ treatment protocols are designed for use by healthcare providers to treat
individuals diagnosed with dependencies to alcohol, cocaine, or methamphetamine as well as
combinations of these drugs. The PROMETA™ protocols include medically supervised treatments
designed to address both the neurochemical imbalances in the brain and some of the nutritional
deficits caused or worsened by substance dependence. Changes in brain chemistry and function play
an important role in the physical and behavioral symptoms of substance dependence, including
tolerance, withdrawal symptoms, craving and relapse. The PROMETA™ protocols also provide for one-
month of prescription medication and nutritional supplements, combined with psychosocial or other
recovery-oriented therapy chosen by the patient in conjunction with their treatment provider. As a
result, PROMETA™ represents an innovative approach to managing alcohol, cocaine or
methamphetamine dependence that is designed to address physiological, nutritional and psychosocial
aspects of the disease, and is thereby intended to offer patients an opportunity to achieve sustained
About Hythiam, Inc.
Hythiam® is a healthcare services management company, focused on delivering solutions for those
suffering from alcoholism and other substance dependencies. Hythiam researches, develops, licenses
and commercializes innovative physiological treatment protocols for substance dependence.
Additionally, Hythiam provides proprietary administrative services to assist physicians and facilities
with staff education, marketing and sales support, and outcomes tracking for data analysis. For
further information please visit www.hythiam.com.
Except for statements of historical fact, the matters discussed in this press release are forward looking and made
pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-
looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which
are beyond the company's control that may cause actual results to differ materially from stated expectations.
These risk factors include, among others, limited operating history and lack of statistically significant formal
research studies, difficulty in developing, exploiting and protecting proprietary technologies, intense competition
and substantial regulation in the healthcare industry; and additional risks factors as discussed in the reports filed
by the company with the Securities and Exchange Commission, which are available on its website at